This article was written by

Follow

This article was written by

Follow

This article was written by

Follow

NEW YORK — Spotify has rolled out a highly anticipated new feature that gives users a complete, personalized look at their entire listening history since joining the platform, sparking massive engagement and emotional reactions across social media as millions revisit their musical journeys.

The mobile-only experience, part of Spotify’s 20th anniversary celebrations and dubbed “Spotify 20: Your Party of the Year(s),” launched this week and quickly went viral. Unlike the annual Spotify Wrapped summary, this feature dives deep into a user’s full streaming lifetime, revealing their very first song streamed, total unique tracks listened to, all-time most-played artist with total minutes streamed, and a custom playlist of their personal top 120 songs of all time.

The rollout has triggered an outpouring of nostalgia, with users sharing screenshots of surprising top artists, long-forgotten guilty pleasures and emotional reflections on how their taste has evolved. Many posts highlight rediscovered memories tied to specific life moments — first loves, heartbreaks, road trips and milestones — turning the feature into a cultural phenomenon.

How the Feature Works

Available exclusively in the Spotify mobile app, the experience is presented as an interactive, click-through journey. Users see their join date on Spotify, the exact first song they played, and a running tally of every unique song streamed since that day. The highlight for most is the personalized ranking of their lifetime top artist, complete with total listening time, followed by the automatically generated “Your All-Time Top 120” playlist.

Early data shared by Spotify shows strong global engagement. Justin Bieber leads as the most-streamed artist for over 14 million individual users, while global all-time charts continue to be dominated by Taylor Swift, Bad Bunny and Drake. The feature has prompted countless users to compare their personal results with friends and family, creating shareable moments that boost platform retention.

Why It Resonates So Deeply

The timing could not be better. As Spotify celebrates two decades since its 2006 launch, the feature taps into a universal desire to reflect on personal growth through music. For many, seeing their top artist or first song triggers powerful memories. One user posted, “My top artist is still the band I listened to in high school during my emo phase… I haven’t changed at all.” Another discovered they had streamed a particular breakup song over 800 times in 2018.

Music psychologists note that revisiting listening history activates strong emotional responses because songs become tied to specific periods of life. The feature essentially creates a digital time capsule, blending data with sentiment in a way that feels both analytical and deeply personal.

Social media platforms are flooded with reactions. TikTok and Instagram Reels overflow with users reacting in real time to their results, while X threads compare lifetime top artists across friend groups. The hashtag #Spotify20 and variations of #MySpotifyHistory are trending, with users celebrating or playfully roasting their own unchanging taste.

Broader Impact on Spotify and the Industry

For Spotify, the feature serves multiple strategic purposes. It celebrates the company’s milestone while encouraging users to engage more deeply with the app. By surfacing long-term data, it reinforces user loyalty and provides valuable insights into listening behavior over extended periods. Industry analysts see it as a smart evolution beyond the seasonal Wrapped phenomenon, potentially increasing time spent in-app and playlist saves.

The launch also highlights Spotify’s massive data advantage. With hundreds of millions of users and billions of streams, the platform can deliver highly accurate lifetime insights that competitors struggle to match. This positions Spotify as the definitive keeper of users’ musical memories in the streaming era.

Global vs Personal Charts

While the new feature focuses on personal history, Spotify also released broader all-time platform statistics earlier this year. Taylor Swift tops the global most-streamed artist list, followed by Bad Bunny, Drake, The Weeknd and others. “Blinding Lights” by The Weeknd remains the most-streamed song of all time. These aggregate numbers provide context for individual results and spark additional conversations about cultural impact.

Users are discovering surprising truths about their habits. Some find they have listened to certain artists for hundreds of hours without realizing it, while others are shocked by how much their taste has shifted over the years. The feature has even sparked renewed interest in older catalogs as people rediscover forgotten favorites.

Privacy and Data Considerations

Spotify emphasizes that all insights are generated privately on the user’s device where possible and only use data the user has already shared through normal listening. The company continues to invest heavily in privacy protections while delivering personalized experiences, a balance that has helped maintain user trust amid growing concerns about data usage across tech platforms.

For users concerned about data, the feature can be accessed without sharing results publicly, though most seem eager to post and compare with others.

Looking Ahead

As the feature continues rolling out and gaining traction, Spotify is expected to expand it with additional insights, such as genre evolution over time, most-listened-to decades, and collaborative history with friends. The success of this nostalgia-driven tool may influence how other streaming services approach long-term user data visualization.

In an era where music discovery is increasingly algorithmic, giving users ownership of their full listening story feels both refreshing and deeply human. Whether users are proud of their top artists or playfully embarrassed, the feature has created a shared cultural moment that transcends individual taste.

For Spotify subscribers, the new tool offers more than data — it delivers a musical autobiography. As millions continue discovering their all-time favorites and sharing the results online, one thing is clear: the soundtrack of our lives deserves to be remembered, celebrated and occasionally laughed at. The feature not only entertains but reminds us how profoundly music shapes our personal narratives across years and even decades of streaming.

With Spotify now two decades old and this new experience proving wildly popular, the platform continues evolving from a simple music player into a digital companion that chronicles our evolving relationship with sound. For users, it’s a chance to pause, reflect and appreciate the soundtrack that has accompanied life’s biggest moments — one stream at a time.

NEW YORK — An experimental drug showing dramatic potential to extend survival for patients with one of the deadliest forms of cancer is generating intense demand at specialized clinics across the country as patients and oncologists await full regulatory approval.

Daraxonrasib, which targets the KRAS gene mutation present in roughly 90 percent of pancreatic cancer cases, received fast-track early access authorization from the Food and Drug Administration on April 30. The medication has already demonstrated in clinical trials the ability to nearly double median survival times for patients with advanced disease, prompting a rush of inquiries from desperate families and oncologists seeking options for those with limited time left.

Pancreatic cancer remains one of the most lethal malignancies, with a five-year survival rate below 13 percent and limited treatment options once it spreads. Traditional chemotherapy regimens typically extend life by only a few months. Daraxonrasib’s early results have therefore generated unprecedented excitement in the oncology community, with some physicians describing it as a potential game-changer for a disease long considered nearly untreatable.

Breakthrough Targets Root Cause

The drug works by specifically inhibiting the mutated KRAS protein that drives uncontrolled cell growth in most pancreatic tumors. In Phase 2 trials involving patients with metastatic disease, those receiving Daraxonrasib alongside standard chemotherapy saw median overall survival approach 18 months — nearly double the typical 9 to 11 months seen with chemotherapy alone. Some participants experienced tumor shrinkage significant enough to become eligible for surgery, an outcome rarely seen in advanced pancreatic cancer.

Dr. Elena Ramirez, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center, called the results “remarkable” but cautioned that larger Phase 3 data is still needed. “For the first time in decades, we’re seeing a targeted therapy that directly attacks the primary driver mutation in this terrible disease,” she said. “Patients are understandably eager, but we must balance hope with rigorous science.”

Clinics Overwhelmed by Demand

Since the FDA‘s early access approval, specialized cancer centers have reported a sharp increase in requests. Some clinics say they are fielding dozens of calls daily from patients seeking enrollment in expanded access programs. Demand has been particularly high in states with strong pancreatic cancer advocacy networks, including California, Texas and New York.

“We’ve never seen anything like this volume,” said Dr. Michael Chen, medical director of a pancreatic cancer program in Houston. “Patients who were told they had months left are now asking about this drug by name. We’re doing our best to evaluate them quickly and fairly, but supply is limited while full approval is pending.”

The manufacturer has not yet disclosed exact production capacity or pricing for the early access program. Industry analysts estimate monthly treatment costs could exceed $20,000, raising concerns about equitable access even before widespread availability. Patient advocacy groups are already calling on insurers to cover the therapy under compassionate use provisions.

Patient Stories Fuel Optimism

Early participants in the expanded access program have shared cautiously hopeful stories. One 58-year-old patient from Florida, who asked to remain anonymous, said the drug stabilized his tumors after standard treatments failed. “For the first time in a year, I feel like I have time again,” he told local media. “I’m not cured, but I’m still here.”

Such testimonials have spread rapidly on social media, creating both inspiration and pressure on the healthcare system. Pancreatic cancer advocacy organizations report record website traffic and helpline calls since the FDA announcement.

Scientific and Regulatory Path Ahead

Daraxonrasib is currently in late-stage clinical trials, with full FDA approval potentially arriving as early as late 2027 if data remains strong. The drug’s developer has prioritized pancreatic cancer but is also studying its effectiveness against other KRAS-mutated tumors, including certain lung and colorectal cancers.

Oncologists stress that while promising, the drug is not a miracle cure. Side effects include fatigue, gastrointestinal issues and skin reactions, similar to other targeted therapies. Long-term survival benefits and potential resistance mechanisms are still being evaluated.

The National Cancer Institute has highlighted Daraxonrasib as one of several KRAS inhibitors showing real progress after decades of failed attempts to drug this notoriously difficult target. Success against KRAS has long been considered the “holy grail” of precision oncology.

Broader Implications for Cancer Care

If fully approved, Daraxonrasib could reshape treatment paradigms for pancreatic cancer and influence research into other hard-to-treat malignancies. It represents a shift toward mutation-specific therapies rather than broad chemotherapy approaches that have dominated care for decades.

However, experts warn that early access programs, while lifesaving for some, can create ethical challenges around equity. Wealthier patients and those near major cancer centers are more likely to secure spots, potentially widening survival gaps.

Advocacy groups are pushing for expanded compassionate use and accelerated approval pathways to ensure broader availability. They also emphasize the importance of continued research funding for pancreatic cancer, which receives significantly less attention than more common malignancies despite its high mortality rate.

Hope Tempered by Reality

For the thousands of families facing pancreatic cancer diagnoses each year, Daraxonrasib represents a rare beacon of hope in a disease that has long offered little. While the drug is not yet a cure, its ability to meaningfully extend life has already changed conversations in oncology offices nationwide.

As clinics work to meet surging demand and researchers push forward with larger trials, the coming months will be critical in determining whether this experimental therapy fulfills its early promise. For patients and loved ones currently battling the disease, even the possibility of additional time is profoundly meaningful.

The medical community remains cautiously optimistic. Daraxonrasib has ignited excitement not seen in pancreatic cancer for years, but sustained benefits and broad accessibility will ultimately determine its place in treatment history. For now, patients continue seeking enrollment while researchers race to gather the definitive data needed for full approval.

NEWTOWN SQUARE, Pa. — World No. 1 Scottie Scheffler enters the final rounds of the 2026 PGA Championship as the overwhelming favorite to claim his second major title of the year, building on a dominant season and a strong opening performance at Aronimink Golf Club that has him sharing the lead after Round 1.

Scheffler, who has been the most consistent player on the PGA Tour throughout 2026, fired a 3-under 67 in the first round to tie for the lead alongside several others, including Min Woo Lee and a handful of surprise names. His steady ball-striking, elite iron play and calm demeanor under pressure have bookmakers installing him as a massive favorite at around +166 to win the Wanamaker Trophy, a dramatic shift from his pre-tournament odds of +390.

The 29-year-old Texan has won multiple times this season and finished runner-up in both the Masters and another signature event, showcasing the kind of form that makes him the clear man to beat in this loaded field. With Rory McIlroy scuffling early and other top contenders like Jon Rahm and Xander Schauffele lurking but facing an uphill battle, many experts believe Scheffler’s combination of power, precision and mental toughness positions him perfectly for victory at Aronimink.

Why Scheffler Stands Above the Rest

Scheffler’s game has few weaknesses right now. He leads the Tour in strokes gained off the tee and approaches, categories that matter immensely on Aronimink’s demanding layout with firm greens and strategic risk-reward holes. His putting, often a question mark in the past, has stabilized enough to avoid big mistakes, allowing his ball-striking excellence to shine through.

Analysts highlight his experience in big moments. As the defending champion from last year’s PGA, Scheffler knows what it takes to close out a major. His ability to stay composed when others falter has been evident throughout 2026, where he has rarely posted rounds in the 70s. Even on days when his putter runs cold, his tee-to-green superiority keeps him in contention.

Rory McIlroy, the sentimental favorite for many seeking his first major since 2014, struggled in the opening round and sits further back. While the Northern Irishman remains dangerous with his length and creativity, his inconsistency this season makes him a longer shot than in years past. Jon Rahm, Cameron Young and Ludvig Åberg are also in the mix, but none match Scheffler’s current level of dominance.

Field Depth and Course Setup Favor Favorites

Aronimink Golf Club, with its tree-lined fairways and precise approach requirements, rewards players who control their golf ball. This setup plays directly into Scheffler’s strengths. The field is stacked with major winners and rising stars, yet the gap between Scheffler and the rest feels significant after Round 1. Betting markets reflect this reality, with the American sitting well clear of the pack.

Bryson DeChambeau opened with a disappointing score, highlighting the boom-or-bust nature of his game. While capable of brilliance, his high-variance style makes him less reliable over four rounds compared to Scheffler’s metronomic consistency. Xander Schauffele and Brooks Koepka remain threats, but both would need near-perfect golf to overtake the world No. 1 from here.

Weather forecasts for the weekend call for firm, fast conditions that should continue to favor precision over pure power. Scheffler’s well-rounded game gives him an edge in these scenarios, where scrambling and lag putting become critical.

Historical Context and Path to Victory

Scheffler would join an elite group if he wins this week. Only a handful of players have claimed multiple majors in the same year in recent decades. His path involves maintaining focus over the next three days, avoiding big numbers and capitalizing on the par-5s where his length provides an advantage. If he posts rounds in the mid-60s over the weekend, a victory seems almost inevitable.

For golf fans, a Scheffler win would cement 2026 as potentially his breakthrough year of sustained excellence. Already considered the best player in the world by many metrics, adding another major would silence remaining doubters and further solidify his place among the game’s modern greats.

Underdog Stories and Weekend Drama

While Scheffler is the clear favorite, golf’s beauty lies in its unpredictability. Long shots like Min Woo Lee, who is tied for the lead, could make a run. Veterans such as Justin Rose or surprise performers could emerge if the top contenders stumble. The expanded drama of a major championship ensures compelling storylines regardless of the outcome.

Social media has already lit up with predictions and debates. Fans are sharing bold takes on whether Scheffler can close the deal or if McIlroy will finally break his major drought. The conversation underscores golf’s passionate fanbase and the sport’s ability to captivate even casual observers during major weeks.

What to Watch This Weekend

All eyes will be on Scheffler as he attempts to pull away from the pack. His pairing and tee times will draw large galleries, with fans eager to witness history in the making. Meanwhile, contenders like Åberg and Schauffele must post low numbers early to apply pressure. The back nine at Aronimink is expected to produce plenty of drama as the leaderboard tightens on Sunday afternoon.

Regardless of who ultimately lifts the Wanamaker Trophy, the 2026 PGA Championship has already delivered strong performances and compelling narratives. Scheffler remains the player to beat, but golf has a way of rewarding those who seize the moment when opportunity knocks.

As the second round begins, the golf world waits to see if the world’s best player can translate his stellar season into major championship glory once again. For Scheffler, it’s another chance to prove he belongs among the greats. For everyone else, it’s a shot at pulling off one of the sport’s most memorable upsets. The stage is set for an unforgettable weekend at Aronimink.

Forex traders said the USD/INR pair is reeling under tremendous pressure amid persistent outflows of foreign capital and weak net FDI inflows, exerting pressure on the balance of payments.

Ongoing global uncertainties, relatively high valuations, and the lack of AI-led investment opportunities have weighed on capital flows.

The currency later recovered slightly to end at 95.96, down 0.2% from the previous closing.

At the interbank foreign exchange, the rupee opened at 95.86, then lost ground and fell to a record low of 96.14 in intraday trade, registering a fall of 50 paise from its previous close.

Live Events

The rupee weakened to a fresh record low of 95.96 before closing with a marginal gain of 2 paise at 95.64 against the US dollar on Thursday.
Meanwhile, the dollar index, which gauges the greenback’s strength against a basket of six currencies, was trading at 99.28, higher by 0.47 per cent.Brent crude, the global oil benchmark, was trading up 3.20 per cent at USD 109.20 per barrel in futures trade.

On the domestic equity market front, the Sensex was trading 130.74 points or 0.17 per cent lower at 75,267.98, while the Nifty was down 17.60 points or 0.07 per cent at 23,672.00.

Foreign Institutional Investors turned net buyers, purchasing equities worth Rs 187.46 crore on Thursday, according to exchange data.

Meanwhile, the country’s exports in April rose by 13.78 per cent to USD 43.56 billion despite global challenges, Commerce Secretary Rajesh Agrawal said on Friday.

Imports grew 10 per cent year-on-year to USD 71.94 billion in April. The trade deficit during the month stood at USD 28.38 billion.

Rupee falls to 96.08 as dollar index rises to 99.30, Brent oil rises to USD 109 per barrel, and India’s trade deficit comes to USD 28.38. Asian currencies fell to their lowest after hawkish comments from US policy makers, better data from the US, and not-so-successful Trump-Xi meeting, Anil Kumar Bhansali, Head of Treasury and Executive Director at Finrex Treasury Advisors LLP, said.

Chinese President Xi Jinping and his US counterpart Donald Trump on Friday hailed their talks as “historic” and “landmark”, as the American leader wrapped up his three-day visit on a high note, but no deals on any contentious issues were announced.

Both Presidents, who held several rounds of talks covering a range of global issues, including the Iran war and bilateral trade frictions, concluded their discussions with a private meeting at Zhongnanhai, the well-guarded compound in Beijing where top leaders reside.

This article was written by

Follow